Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

686
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

738
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

821
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

626
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of recurrence and functional status in young ischemic stroke patients: Comparison of machine learning and traditional statistical methods.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Guillain-Barré Syndrome Disability Scale.

Journal of the peripheral nervous system : JPNS·2025
Same author

Unlocking the Future of Alzheimer's Disease: Innovations in Diagnosis and Therapy.

The Journal of the Association of Physicians of India·2025
Same author

Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.

CNS drugs·2025
Same author

Continuing medical education in epileptology: The Level 1-2-3 experience of the ILAE academy.

Epileptic disorders : international epilepsy journal with videotape·2025
Same author

Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021.

JAMA neurology·2025

Related Experiment Video

Updated: Apr 19, 2026

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.6K

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Richard A C Hughes1, Man Mohan Mehndiratta

  • 1MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK.

The Cochrane Database of Systematic Reviews
|January 7, 2015
PubMed
Summary

Corticosteroids show limited evidence of benefit for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Prednisone did not significantly improve outcomes compared to no treatment, while dexamethasone and prednisolone showed similar efficacy with fewer side effects for dexamethasone.

More Related Videos

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

20.0K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

3.0K

Related Experiment Videos

Last Updated: Apr 19, 2026

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

3.6K
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
09:44

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

20.0K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

3.0K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disorder causing progressive paralysis.
  • Corticosteroids are commonly used to treat CIDP, with prednisone, prednisolone, and dexamethasone being frequent choices.

Purpose of the Study:

  • To evaluate the effectiveness of corticosteroid treatments versus placebo or no treatment for CIDP.
  • To compare different corticosteroid regimens for CIDP management.

Main Methods:

  • Searched multiple databases for randomized controlled trials (RCTs) of corticosteroids for CIDP.
  • Included randomized or quasi-randomized trials using internationally accepted CIDP diagnostic criteria.
  • Extracted data and assessed risk of bias independently.

Main Results:

  • One small, non-blinded RCT (35 participants) showed a non-significant trend for prednisone improving neuropathy impairment scores compared to no treatment.
  • A double-blind RCT (40 participants) found no significant difference in remission or disability between daily prednisolone and monthly high-dose dexamethasone.
  • Adverse events were similar, but monthly dexamethasone had less sleeplessness and moon facies.

Conclusions:

  • Very low-quality evidence from one RCT suggests no statistically significant benefit of oral prednisone over no treatment for CIDP.
  • Moderate-quality evidence indicates similar efficacy between daily prednisolone and monthly high-dose dexamethasone, with a better side effect profile for dexamethasone.
  • Further research is needed to identify predictors of corticosteroid response in CIDP.